Insilico Medicine, a clinical-stage biotechnology company specialising in generative artificial intelligence (AI)-driven drug discovery, has announced a proposed multi-target strategic alliance with Bora Pharmaceuticals, a pharmaceutical development and manufacturing company, to accelerate AI-enabled drug discovery, development and commercialisation.

Subject to the execution of definitive agreements, the collaboration seeks to combine Insilico's proprietary Pharma.AI platform—which spans target discovery, generative chemistry and molecule optimisation—with Bora's expertise in pharmaceutical development, manufacturing, quality systems and commercialisation. The companies aim to establish an integrated innovation model that links AI-powered drug discovery with large-scale development and manufacturing capabilities to accelerate the delivery of new therapies for patients with unmet medical needs.

The alliance is expected to create a broad multi-target collaboration framework with a potential value exceeding USD 2.5 billion, if fully implemented. Beyond drug discovery, the partnership will also focus on strengthening Bora's AI capabilities across its global operations, including manufacturing, supply chain management, distribution and corporate functions, while enhancing AI literacy throughout the organisation.

As part of the collaboration, Insilico plans to support Bora's transition towards AI- and automation-driven research and development by providing end-to-end AI solutions and strategic support across global drug discovery and development workflows. The companies also intend to explore the application of AI and automation in development planning, pharmaceutical process optimisation, manufacturing readiness and quality management systems.

The partnership reflects a shared vision of building an AI-native, data-driven and automation-enabled biopharmaceutical ecosystem where innovation extends beyond molecule discovery to encompass the entire drug development and manufacturing value chain. By combining Insilico's AI-driven discovery platform with Bora's expertise in chemistry, manufacturing and controls (CMC), regulatory development, commercial manufacturing and global supply chain management, the companies aim to create a more efficient pathway from discovery to commercialisation.

Commenting on the partnership, Bobby Sheng, Founder and Chairman of Bora Group and CEO of Bora Pharmaceuticals, said the alliance represents a significant step in the company's evolution from a pharmaceutical development and manufacturing partner to an integrated drug innovation organisation. He noted that combining AI-enabled drug discovery with Bora's global manufacturing and commercial capabilities would help establish a scalable model for accelerating the development and commercialisation of innovative therapies.

Dr. Alex Zhavoronkov, Founder, Co-CEO and Chief Business Officer of Insilico Medicine, said the collaboration builds on the company's growing partnerships across the Asia-Pacific region and demonstrates its commitment to integrating AI-driven drug discovery with downstream development and manufacturing capabilities. He added that the alliance would help demonstrate how AI-discovered medicines can be developed more rapidly, efficiently and at greater scale.

Insilico has emerged as one of the leading AI-driven drug discovery companies globally. The company reports that while conventional early-stage drug discovery typically requires between 2.5 and 4 years, its AI-enabled platform has consistently achieved preclinical candidate nomination within 12 to 18 months. Since 2021, Insilico has nominated 31 preclinical candidates, with 13 receiving Investigational New Drug (IND) approval or clearance.

Alongside its drug discovery platform, the company continues to expand its AI capabilities through MMAI Gym, a scientific AI benchmarking and training platform designed to support domain-specific reasoning models. The platform has attracted collaborations with organisations including Human Longevity and Liquid AI, supporting Insilico's broader objective of advancing AI applications across pharmaceutical research and life sciences.

The proposed partnership underscores the growing role of artificial intelligence in transforming pharmaceutical R&D by integrating AI-enabled discovery with development, manufacturing and commercial execution to improve the speed and efficiency of bringing new medicines to market.